Archive | February, 2018

Cannabinoids prevent depressive-like symptoms and alterations in BDNF expression in a rat model of PTSD.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 16. pii: S0278-5846(17)31000-X. doi: 10.1016/j.pnpbp.2018.01.026. [Epub ahead of print] Burstein O1, Shoshan N2, Doron R1, Akirav I3. Author information Abstract Posttraumatic stress disorder (PTSD) is a debilitating condition highly comorbid with depression. The endocannabinoid (eCB) system and brain-derived neurotrophic factor (BDNF) are suggestively involved in both disorders. We examined […]

Simplified guideline for prescribing medical cannabinoids in primary care.

Can Fam Physician. 2018 Feb;64(2):111-120. Allan GM1, Ramji J2, Perry D2, Ton J2, Beahm NP3, Crisp N4, Dockrill B5, Dubin RE6, Findlay T7, Kirkwood J8, Fleming M9, Makus K10, Zhu X11, Korownyk C12, Kolber MR13, McCormack J14, Nickel S15, Noël G16, Lindblad AJ17. Author information Abstract OBJECTIVE: To develop a clinical practice guideline for a […]

Clinicians Support Medical Marijuana Use in Children With Cancer, But Lack Knowledge

New Online Views 708 Citations 0 24 Medical News & Perspectives February 14, 2018 Rachel Rabkin Peachman Article Information JAMA. Published online February 14, 2018. doi:10.1001/jama.2018.0089   Seth Perlman/AP Images   When medical marijuana was legalized in Massachusetts 5 years ago, Emma Jones, MD, was one of the first physicians on the pediatric palliative care team at […]

The impact of PTSD clusters on cannabis use in a racially diverse trauma-exposed sample: An analysis from ecological momentary assessment.

Am J Drug Alcohol Abuse. 2018 Feb 14:1-11. doi: 10.1080/00952990.2018.1430149. [Epub ahead of print] Buckner JD1, Jeffries ER1, Crosby RD2,3, Zvolensky MJ4,5, Cavanaugh CE6, Wonderlich SA2,3. Author information Abstract BACKGROUND: Accumulating evidence indicates a link between post-traumatic stress disorder (PTSD) and cannabis use and suggests that this link may vary as a function of the PTSD […]

Cannabis for paediatric epilepsy: challenges and conundrums.

Med J Aust. 2018 Feb 19;208(3):132-136. Chen KA1, Farrar MA2, Cardamone M2, Lawson JA2. Author information Abstract Research is expanding for the use of cannabidiol as an anticonvulsant drug. The mechanism of cannabidiol in paediatric epilepsy is unclear but is thought to play a role in modulation of synaptic transmission. Evidence for its efficacy in […]

Regulating Cannabis Manufacturing: Applying Public Health Best Practices from Tobacco Control.

J Psychoactive Drugs. 2018 Feb 13:1-14. doi: 10.1080/02791072.2017.1422816. [Epub ahead of print] Orenstein DG1, Glantz SA2. Author information Abstract State legalization and regulation of cannabis, despite continued federal illegality, is a massive shift in regulatory approach. Manufactured cannabis, including concentrates, extracts, edibles, tinctures, topicals and other products, has received less attention than more commonly used […]

The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.

Curr Neurol Neurosci Rep. 2018 Feb 13;18(2):8. doi: 10.1007/s11910-018-0814-x. Nielsen S1, Germanos R2, Weier M2,3, Pollard J4, Degenhardt L2, Hall W3, Buckley N4, Farrell M2. Author information Abstract PURPOSE OF REVIEW: Pharmaceutical cannabinoids such as nabiximols, nabilone and dronabinol, and plant-based cannabinoids have been investigated for their therapeutic potential in treating multiple sclerosis (MS) symptoms. […]

Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis.

J Physiol Biochem. 2018 Feb 13. doi: 10.1007/s13105-018-0611-7. [Epub ahead of print] Fonseca BM1, Correia-da-Silva G2, Teixeira NA2. Author information Abstract Among a variety of phytocannabinoids, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most promising therapeutic compounds. Besides the well-known palliative effects in cancer patients, cannabinoids have been shown to inhibit in vitro growth of […]

Plasma N-acylethanolamine and endocannabinoid levels in burning mouth syndrome: potential role in disease pathogenesis.

J Oral Pathol Med. 2018 Feb 13. doi: 10.1111/jop.12692. [Epub ahead of print] Barry A1, O’Halloran KD1, McKenna JP2, McCreary C2, Harhen B3,4, Kerr DM3,4, Finn DP3,4, Downer EJ5. Author information Abstract OBJECTIVE: The objective was to measure endocannabinoid (eCB) ligands and non-cannabinoid N-acylethanolamine (NAE) molecules in plasma from individuals with burning mouth syndrome (BMS), […]

Neuroprotective Effects of MAGL (Monoacylglycerol Lipase) Inhibitors in Experimental Ischemic Stroke.

Stroke. 2018 Feb 13. pii: STROKEAHA.117.019664. doi: 10.1161/STROKEAHA.117.019664. [Epub ahead of print] Choi SH1, Arai AL1, Mou Y1, Kang B1, Yen CC1, Hallenbeck J1, Silva AC2. Author information Abstract BACKGROUND AND PURPOSE: MAGL (monoacylglycerol lipase) is an enzyme that hydrolyzes the endocannabinoid 2-arachidonoylglycerol and regulates the production of arachidonic acid and prostaglandins-substances that mediate tissue […]